RSPE yields 1.67% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, RSPE + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RSPE + PFE for your $10,000?
The Invesco ESG S&P 500 Equal Weight ETF (Fund) is based on the S&P 500 Equal Weight Scored & Screened Leaders Select Index (Index). The Fund will invest at least 90% of its total assets in securities that comprise the Index. The Index is designed to measure the equal weighted performance of securities included in the S&P 500 Equal Weight Index that also meet an environmental, social and governance (“ESG”) criteria, while maintaining similar overall industry group weights as the S&P 500 Equal Weight Index. Each security is given an “ESG score” that seeks to identify companies well-equipped to recognize and respond to emerging sustainability opportunities and challenges in the global market. Industry-specific questionnaires are used to analyze companies’ custom industries derived from Global Industry Classification Standard (“GICSS&P 500”). Companies provide up to 1,000 data points in response to the questionnaires which is used to score each company’s performance in relation to each specific ESG subject. If a company chooses not to actively participate in the assessment, it may be assessed based on publicly available information. Companies are ranked from highest to lowest according to their ESG scores, and the top 40% of constituents within each GICS S&P 500 industry group generally are included in the Index. The Fund and the Index are rebalanced quarterly. Effective after close of business February 10, 2025, the S&P 500 Equal Weight ESG Leaders Select Index changed its name to the S&P 500 Equal Weight Scored & Screened Leaders Select Index. The underlying index and methodology remains the same.
Full RSPE Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.